The Effect of BEPREVE 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer
This study is ongoing, but not recruiting participants.
Sponsor:
Minnesota Eye Consultants, P.A.
Collaborator:
Bausch & Lomb Incorporated
Information provided by (Responsible Party):
Minnesota Eye Consultants, P.A.
ClinicalTrials.gov Identifier:
NCT01346371
First received: April 29, 2011
Last updated: August 7, 2012
Last verified: August 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to compare the effect of Bepreve® with an artificial-tear eye drop on the quality of your tears.
| Condition | Intervention | Phase |
|---|---|---|
|
Allergic Conjunctivitis |
Drug: Bepreve (bepotastine ophthalmic solution) 1.5% |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | The Effect of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer |
Resource links provided by NLM:
Further study details as provided by Minnesota Eye Consultants, P.A.:
Primary Outcome Measures:
- Tear Osmolarity [ Time Frame: 56 days after initial screening visit ] [ Designated as safety issue: No ]The TearLab Osmolarity System will be used to assess tear film osmolarity.
| Enrollment: | 40 |
| Study Start Date: | May 2011 |
| Estimated Study Completion Date: | August 2012 |
| Estimated Primary Completion Date: | August 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Placebo Comparator: Refresh Tears® eye drops
Must add drops twice a day every day during trial enrollment.
|
|
|
Experimental: Bepreve® 1.5% solution
Must add drops twice a day every day while enrolled in trial.
|
Drug: Bepreve (bepotastine ophthalmic solution) 1.5%
Must add drops twice a day every day while enrolled in trial.
|
Detailed Description:
This is a single-center, randomized, parallel group, placebo-controlled study to evaluate the effect of BEPREVE compared to a placebo eye drop on the measurement of tear film osmolarity and tear film lipid layer in patients with allergic conjunctivitis.
Subjects will be screened for this study on day one of dosing with the test article. Subjects who sign the informed consent form and who meet all inclusion/exclusion criteria will be eligible for participation in this study. They will be assigned sequentially, according to a computer generated randomization list, in a ratio of 1:1 to receive either BEPREVE™ (bepotastine besilate ophthalmic solution) 1.5% or REFRESH TEARS® Lubricant Eye Drops (1:1). Subjects will instill one drop of test article either BEPREVE™ or REFRESH TEARS® into the study eyes twice daily for a maximum of 60 days. Subjects will be seen for evaluation on Days 0, 28±3, and 56±3 following randomization.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Are male or female at least 18 years of age who are diagnosed with allergic conjunctivitis.
- Have documented positive skin prick puncture test to at least one (1) seasonal allergen (e.g., grasses, trees, weeds, or other allergens) within two (2) years of Visit 1.
- Agree not to have any other ocular drops in study eyes within 2 days prior to the initiation of dosing with the test article or throughout the duration of the study.
- Have a Best Corrected Visual Acuity of 20/200 or better in either eye.
- Are willing/able to follow instructions from the study investigator and his/her staff.
- Be willing/able to return for all required study visits, to follow instructions from the study investigator and his/her staff.
- Are able to self-administer test article (or have a caregiver available to instill all doses of test article).
- Have signed informed consent approved by Institutional Review Board or Independent Ethics Committee.
Exclusion Criteria:
- Have known hypersensitivity to either BEPREVE™ or REFRESH TEARS® or to any component of the test article (including "procedural" medications such as anesthetic and/or fluorescein drops, dilating drops, etc.).
- Have active corneal pathology noted in the study eye at the screening visit. Active corneal pathology is defined as corneal pathology that is non-stable, or greater than mild, or will compromise assessment of the safety or efficacy of treatment.
- Have used topical, ocular, inhaled or systemic steroids within 14 days prior to screening.
- Have a history of abuse of alcohol/drugs within six months prior to the screening visit.
- Are pregnant or nursing/lactating.
- Have participated in any other study of an investigational drug or device within 30 days prior to randomization.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01346371
Locations
| United States, Minnesota | |
| Minnesota Eye Consultants, P.A. | |
| Minneapolis, Minnesota, United States, 55404 | |
Sponsors and Collaborators
Minnesota Eye Consultants, P.A.
Bausch & Lomb Incorporated
Investigators
| Principal Investigator: | Ahmad M Fahmy, O.D. | Minnesota Eye Consultants |
More Information
Additional Information:
No publications provided
| Responsible Party: | Minnesota Eye Consultants, P.A. |
| ClinicalTrials.gov Identifier: | NCT01346371 History of Changes |
| Other Study ID Numbers: | MAC-01-11 |
| Study First Received: | April 29, 2011 |
| Last Updated: | August 7, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Minnesota Eye Consultants, P.A.:
|
Allergic conjunctivitis Allergic conjunctivitis |
Additional relevant MeSH terms:
|
Conjunctivitis Conjunctivitis, Allergic Conjunctival Diseases Eye Diseases |
Hypersensitivity, Immediate Hypersensitivity Immune System Diseases |
ClinicalTrials.gov processed this record on May 19, 2013